acceso a medicamentos

Oxfam has hailed the Indian Supreme Court’s ruling against a patent protection petition filed by multinational pharmaceutical company Novartis as a huge victory for public health.

 

 

New Oxfam report: The proliferation of substandard medicines in poor countries is being used by rich countries as an excuse to tighten intellectual property rules, boosting the profits of large pharmaceutical companies while making it harder for poor people to get access to the medicines they need.

Poor-quality, or “substandard”, medicines threaten patients and public health in developing countries.

World leaders made no real commitments to ensure universal access to prevention, treatment and care for AIDS at this week's International AIDS conference in Vienna.

Access to medicines poses a critical challenge in developing countries: prices are high, and new or adapted medicines and vaccines to address diseases of the developing world are lacking.

17 Feb – Pharmaceutical giant GlaxoSmithKline should be congratulated for breaking industry ranks and taking a major step toward helping poor people in developing countries to get better access to medicines, says international agency Oxfam. However GSK’s initiative this week is just the beginning.

Rich country donors and the World Bank are wasting money and risking lives by continuing to push unproven and discredited private healthcare programs in poor countries. Oxfam’s warning comes in a new report ‘Blind Optimism: Challenging the myths about private health care in poor countries’.